Sun Pharmaceutical Industries Ltd - Company Profile

Powered by

All the data and insights you need on Sun Pharmaceutical Industries Ltd in one report.

  • Save hours of research time and resources with
    our up-to-date Sun Pharmaceutical Industries Ltd Strategy Report

  • Understand Sun Pharmaceutical Industries Ltd position in the market,
    performance and strategic initiatives.

  • Gain competitive edge and increase your
    chances of success

Back to companies

Sun Pharmaceutical Industries Ltd: Overview

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward

Sun Pharmaceutical Industries Ltd (Sun Pharma) is a specialty pharmaceutical company that offers an array of pharmaceutical formulations such as branded generics and generic pharmaceuticals. The company’s portfolio includes products for the treatment of psychiatric, neurological, nephrological, gastroenterological, orthopedic and ophthalmologic diseases and disorders, and heart diseases. The company carries out product development, process chemistry, and manufacture of complex formulations, active pharmaceutical ingredients (APIs) and over-the-counter products. It offers drugs in various dosage forms such as tablets, capsules, injectables, inhalers, ointments, creams, and liquids. The company has manufacturing facilities in North America, Latin America, EMEA and Asia Pacific. Sun Pharma is headquartered in Mumbai, Maharashtra, India.

Gain a 360-degree view of Sun Pharmaceutical Industries Ltd and make more informed decisions for your business Gain a 360-degree view of Sun Pharmaceutical Industries Ltd and make more informed decisions for your business Find out more
Headquarters India

Address Sun House, Cts No. 201 B/1, Western Exp, Mumbai, Maharashtra, 400093


Telephone 91 22 43244324

No of Employees 41,000

Industry Pharmaceuticals and Healthcare

Ticker Symbol & Exchange SUNPHARMA (NSE)

Revenue (2023) $5.9B 10.5% (2023 vs 2022)

EPS XYZ

Net Income (2023) XYZ 13% (2023 vs 2022)

Market Cap* $42.9B

Net Profit Margin (2023) XYZ 2.3% (2023 vs 2022)

* As of and is in US$
Gain access to our premium signals and make informed decisions for your business Gain access to our premium signals and make informed decisions for your business Find out more

Sun Pharmaceutical Industries Ltd premium industry data and analytics

1,100+

Marketed Drugs

Understand Sun Pharmaceutical Industries Ltd’s commercialized product portfolio to stay one step ahead of the market.

690+

Clinical Trials

Determine Sun Pharmaceutical Industries Ltd go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

270+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for Sun Pharmaceutical Industries Ltd’s relevant decision makers and contact details.

220+

Catalyst Calendar

Proactively evaluate Sun Pharmaceutical Industries Ltd’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

70+

Pipeline Drugs

Identify which of Sun Pharmaceutical Industries Ltd’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

20+

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

17+

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

1

ICT Spend & Tech Priorities

IT Client Prospector provides intelligence on Sun Pharmaceutical Industries Ltd’s likely spend across technology areas enabling you to understand the digital strategy.

Products and Services

Products Brands
Product Categories: Amixide
Formulations Alzolam-Sr
Active Pharmaceutical Ingredients Amlosun
XYZ XYZ
XYZ XYZ
XYZ XYZ
Understand Sun Pharmaceutical Industries Ltd portfolio and identify potential areas for collaboration Understand Sun Pharmaceutical Industries Ltd portfolio and identify potential areas for collaboration Find out more

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2024 Acquisitions/Mergers/Takeovers In January, the company acquired all the shares of Taro Pharmaceutical Industries.
2024 Contracts/Agreements In June, the company signed an agreement to acquire a 9.6% stake in HaystackAnalytics Private Limited.
2024 Contracts/Agreements In May, the company signed an agreement to acquire Valstar Investment S.a.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Find out more
Image for loader

Competitor Comparison

Key Parameters Sun Pharmaceutical Industries Ltd Pfizer Inc Sanofi Novartis AG Fresenius SE & Co KGaA
Headquarters India United States of America France Switzerland Germany
City Mumbai New York Paris Basel Bad Homburg
State/Province Maharashtra New York Ile-de-France - Hessen
No. of Employees 41,000 88,000 87,994 76,057 190,863
Entity Type Public Public Public Public Public
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
Name Position Board Since Age
Dilip S. Shanghvi Director; Managing Director Executive Board 2012 67
C. S. Muralidharan Chief Financial Officer Senior Management 2017 -
Dheeraj Sinha Executive Vice President; Chief Information Officer Senior Management 2024 -
Suresh Kumar Rai Senior Vice President; Chief Human Resources Officer Senior Management 2023 -
Aalok D. Shanghvi Executive Vice President - Emerging Markets, Global generic R&D, Global BD (Generics Segment) & API; Director Executive Board 2023 -
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Gain insight into Sun Pharmaceutical Industries Ltd key executives to enhance your sales strategy Gain insight into Sun Pharmaceutical Industries Ltd key executives to enhance your sales strategy Find out more
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Why are you leaving?